Cargando…
The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
BACKGROUND: An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. METHODS: A meta-analysis was performed to assess the correlation between le...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708253/ https://www.ncbi.nlm.nih.gov/pubmed/33256658 http://dx.doi.org/10.1186/s12885-020-07651-1 |
_version_ | 1783617526687596544 |
---|---|
author | Zhang, Lilong Yuan, Qihang Li, Man Chai, Dongqi Deng, Wenhong Wang, Weixing |
author_facet | Zhang, Lilong Yuan, Qihang Li, Man Chai, Dongqi Deng, Wenhong Wang, Weixing |
author_sort | Zhang, Lilong |
collection | PubMed |
description | BACKGROUND: An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. METHODS: A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. RESULTS: Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). CONCLUSION: The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis. |
format | Online Article Text |
id | pubmed-7708253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77082532020-12-02 The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis Zhang, Lilong Yuan, Qihang Li, Man Chai, Dongqi Deng, Wenhong Wang, Weixing BMC Cancer Research Article BACKGROUND: An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. METHODS: A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. RESULTS: Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). CONCLUSION: The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis. BioMed Central 2020-11-30 /pmc/articles/PMC7708253/ /pubmed/33256658 http://dx.doi.org/10.1186/s12885-020-07651-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Zhang, Lilong Yuan, Qihang Li, Man Chai, Dongqi Deng, Wenhong Wang, Weixing The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis |
title | The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis |
title_full | The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis |
title_fullStr | The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis |
title_full_unstemmed | The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis |
title_short | The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis |
title_sort | association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708253/ https://www.ncbi.nlm.nih.gov/pubmed/33256658 http://dx.doi.org/10.1186/s12885-020-07651-1 |
work_keys_str_mv | AT zhanglilong theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT yuanqihang theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT liman theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT chaidongqi theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT dengwenhong theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT wangweixing theassociationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT zhanglilong associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT yuanqihang associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT liman associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT chaidongqi associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT dengwenhong associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis AT wangweixing associationofleptinandadiponectinwithhepatocellularcarcinomariskandprognosisacombinationoftraditionalsurvivalanddoseresponsemetaanalysis |